%0 Journal Article
%T Factor VII recombinante activado en pacientes no hemof¨ªlicos con hemorragia aguda grave en la Unidad de Terapia Intensiva
%A Carrillo-Esper
%A Ra¨²l
%A S¨¢nchez-Z¨²£¿iga
%A Mart¨ªn de Jes¨²s
%A Elizondo-Argueta
%A Sandra
%A Visoso-Palacios
%A Porfirio
%A Carrillo-C¨®rdova
%A Jorge Ra¨²l
%J Gaceta m¨¦dica de M¨¦xico
%D 2006
%I Scientific Electronic Library Online
%X background. severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. recombinant factor viia (rfviia) constitutes a new therapeutic alternative. objective. analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rfviia. material and methods. ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rfviia. we used a t test for statistic analyses. significance was set at p < 0.001. results. among patients treated with rfviia, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). conclusions. rfviia is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.
%K recombinant factor viia
%K severe hemorrhage
%K coagulation cell model.
%U http://www.scielo.org.mx/scielo.php?script=sci_abstract&pid=S0016-38132006000500002&lng=en&nrm=iso&tlng=en